SNDX

SYNDAX PHARMACEUTICALS INC

Healthcare | Small Cap

-$0.51

EPS Forecast

$80.36

Revenue Forecast

The company already released most recent quarter's earnings. We will publish our AI's next quarter's forecast around 2026-12-31

Syndax’s Q2 2026 Revenue Momentum: Big Top-Line, Bigger Pipeline Catalysts

Ticker: SNDX | Nasdaq: SNDX | EPS: not disclosed in the release; EPS consensus to watch | Revenue forecast: guidance pending; Earnings surprise risks loom as analysts parse two revenue lines vs. the reported total

Executive snapshot

Syndax Pharmaceuticals, trading as SNDX on the Nasdaq, reported its second-quarter 2026 results with a headline that sounds like a chorus: revenue is up, pipeline is louder, and data readouts are scheduled for late 2026. The company emphasizes a multi-product revenue story and a push into next‑generation oncology and fibrosis programs.

The press release highlights a total revenue figure for 2Q26 of $73 million, a 92% year-over-year increase. It also breaks out product-level standalone numbers that appear to exceed the top-line figure in aggregate, a quirk analysts will want to reconcile on the call. Specifically, the release lists Revuforj net revenue of $54.7 million (up 91% YoY) and Niktimvo (axatilimab-csfr) net revenue of $60.3 million (up 67% YoY), plus $18.1 million of collaboration revenue. In short, the narrative is “growth across two core medicines with a sprinkle of partner-driven dollars.”

The company quotes CEO Michael A. Metzger underscoring progress toward frontline AML with Revuforj, growth in cGVHD and IPF indications via Niktimvo, and ongoing pipeline expansion—an unusual mix that makes the quarter feel less like a single KPI and more like a product catalog of opportunities.

What the numbers imply (and what they don’t)

The most eye-catching element is the contrast between the $73 million total revenue and the triple tally of product and collaboration revenues that, on their face, would exceed that total when added together. That discrepancy is not unusual in corporate press releases: “net revenue” lines can capture different accounting treatments or timing, while the top-line figure may reflect a consolidated view. Investors will want to see a clean reconciliation in the 8-K or during the earnings call.

From an investor-instrument lens, the absence of an explicit EPS figure or a formal EPS consensus presents a watch item. In practice, the stock reaction often hinges on whether the revenue drivers translate into earnings per share momentum, even if the company emphasizes top-line growth and pipeline value. Traders will also scan for any earnings surprise or guidance updates in the subsequent quarter when the company provides a fuller view of profitability and cost discipline.

The narrative focuses on two revenue engines—Revuforj and Niktimvo—tied to a broader theme: a robust, diversified pipeline that the company frames as “first- and best-in-class potential” in EGFR-mutated NSCLC and a novel Menin inhibitor program for myelofibrosis. This dual engine could attract different investor tribes: one focused on late-stage value creation from oncology assets, the other on next-generation targets in hematologic malignancies and fibrotic indications.

Pipeline and near-term catalysts

The company underscores near-term data catalysts: topline readouts in 4Q26 from Phase 2 trials of axatilimab (N/A IPF and frontline cGVHD) and continued advancement of Revuforj and Niktimvo across indications. The emphasis on milestones suggests the company is balancing current revenue momentum with a disciplined pipeline timetable.

Beyond these programs, Syndax points to two recently announced assets with “first- and best-in-class potential” in EGFR-mutated NSCLC and a live, internally developed next-generation menin inhibitor for myelofibrosis. If those programs mature toward meaningful data and regulatory strategy, the firm could shift from a revenue-centric narrative to a pipeline-led growth story, potentially altering the competitive dynamics in immuno-oncology and epigenetic targeting.

Market implications and sector outlook

For sector peers, Syndax’s Q2 narrative reinforces a broader investor appetite for diversified oncology portfolios anchored by select, high-potential assets. The combination of commercial-stage revenue (Revuforj and Niktimvo) with a pipeline that spans EGFR-targeted oncology and menin inhibition may signal a bifurcated value proposition: near-term earnings visibility versus long-range data-driven upside.

The absence of a disclosed revenue forecast for the full year makes revenue forecast a live variable for analysts. If the 4Q26 topline data in IPF and frontline cGVHD lands positively, and if the EGFR-mutated NSCLC and myelofibrosis programs begin to contribute meaningfully, Syndax could see its earnings narrative shift from “growth from two medicines” to “growth from a broader, multi-asset platform.” That has implications for peers pursuing menin inhibitors, EGFR-NSCLC, or multi-asset oncology franchises.

Takeaways

  • SNDX reports strong 2Q26 top-line growth, driven by Revuforj and Niktimvo, with a leaned‑in collaboration component.
  • The EPS and full-year revenue forecast are not detailed in the release, leaving room for a classic post-earnings interpretation cycle around EPS consensus expectations.
  • Near-term milestones in 4Q26 and additional data readouts for IPF, cGVHD, and the two newly highlighted assets could catalyze a more expansive growth narrative for the stock and its sector peers.
  • Investors should watch for how the company reconciles the top-line figures with the product-level revenues and whether the enterprise can translate pipeline value into sustained profitability.

In Matt Levine’s parlance: the press release reads like a well-structured product catalog with a conference-call invitation stapled to the bottom. The real question is whether the catalog sells, or merely foreshadows a future where the inventory management—the pipeline—begins to drive earnings in a more tangible way.

Conference call: today at 4:30 p.m. ET. For investors, the next lines will be as important as the numbers: the EPS trajectory, the revenue forecast clarity, and the pace at which pipeline catalysts convert into cash and clinical outcomes.